


Table B.1.b. CVD mortality: Association between physical activity and CVD mortality among adults (in alphabetical order by author)

See the [Supplementary materials](#) for description of evidence of US PAGAC by outcome

Systematic review evidence Review credibility	No. of studies/ Study design No. of participants	Quality Assessment					Description of evidence Summary of findings	Certainty																																																																								
		Risk of bias	Inconsistency	Indirectness†	Imprecision	Other																																																																										
Blond 2019 (11) Moderate	48 prospective cohort studies N=NR	No serious risk of bias	Serious inconsistency	No serious indirectness	No serious imprecision	Possible publication bias Evidence of a dose-response relationship	<p>Five studies used accelerometers to measure PA while all other studies used self-reported PA. Eight measures included occupational PA. Most studies focused on MVPA or leisure-time PA.</p> <p>An inverse relationship was found between PA and CVD mortality (p non-linearity <0.001). The mortality risk was lower for all PA levels above the recommended level compared with the recommended level (750 MET min/week). Compared with 750 MET min/week, those participating in 2000 MET min/week (4 hrs/week) had a statistically significantly lower risk of all-cause mortality (HR = 0.81 [95% CI, 0.77 to 0.85]) with an ARD = -5 deaths per 10,000 person years [95% CI, -6 to -4 deaths).</p>  <p>Figure 3 Dose-response relationship between physical activity and cardiovascular disease (CVD) mortality. Dose-response relationship between metabolic equivalent of task (MET) min/week (with 750 MET min/week as the reference) and mortality risk estimated with restricted cubic regression and generalised least square trend estimation for summarised dose-response data.</p> <table border="1"> <caption>Table 1 Mortality HRs with 750 metabolic equivalent of task (MET) min/week as reference and estimated absolute rate differences per 100 person years</caption> <thead> <tr> <th>MET min/week</th> <th>0</th> <th>500</th> <th>1000</th> <th>2000</th> <th>3000</th> <th>4000</th> <th>5000</th> <th>6000</th> </tr> </thead> <tbody> <tr> <td>Running (5 mph)*</td> <td>0 hours/week</td> <td>1 hour/week</td> <td>2 hours/week</td> <td>4 hours/week</td> <td>6 hours/week</td> <td>8 hours/week</td> <td>10 hours/week</td> <td>12 hours/week</td> </tr> <tr> <td>CVD mortality</td> <td>Studies: 15</td> <td>18</td> <td>18</td> <td>17</td> <td>8</td> <td>2</td> <td>2</td> <td>NA</td> </tr> <tr> <td></td> <td>Participants†: 579 901</td> <td>986 340</td> <td>279 319</td> <td>286 717</td> <td>111 007</td> <td>19 489</td> <td>5488</td> <td>NA</td> </tr> <tr> <td></td> <td>Py†: 7721 115</td> <td>9 761 494</td> <td>3 860 943</td> <td>3 796 251</td> <td>1 165 769</td> <td>274 344</td> <td>65 089</td> <td>NA</td> </tr> <tr> <td></td> <td>Total cases†: 12 318</td> <td>30 196</td> <td>8618</td> <td>8661</td> <td>3258</td> <td>486</td> <td>87</td> <td>NA</td> </tr> <tr> <td></td> <td>HR (95% CI): 1.34 (1.26 to 1.42)</td> <td>1.08 (1.07 to 1.10)</td> <td>0.93 (0.91 to 0.94)</td> <td>0.81 (0.77 to 0.85)</td> <td>0.78 (0.69 to 0.87)</td> <td>0.75 (0.63 to 0.91)</td> <td>0.73 (0.56 to 0.95)</td> <td>NA</td> </tr> <tr> <td></td> <td>ARD (95% CI)†: 8 (6 to 10)</td> <td>2 (2 to 2)</td> <td>-2 (-2 to -1)</td> <td>-5 (-6 to -4)</td> <td>-5 (-8 to -3)</td> <td>-6 (-9 to -2)</td> <td>-7 (-11 to -1)</td> <td>NA</td> </tr> </tbody> </table>	MET min/week	0	500	1000	2000	3000	4000	5000	6000	Running (5 mph)*	0 hours/week	1 hour/week	2 hours/week	4 hours/week	6 hours/week	8 hours/week	10 hours/week	12 hours/week	CVD mortality	Studies: 15	18	18	17	8	2	2	NA		Participants†: 579 901	986 340	279 319	286 717	111 007	19 489	5488	NA		Py†: 7721 115	9 761 494	3 860 943	3 796 251	1 165 769	274 344	65 089	NA		Total cases†: 12 318	30 196	8618	8661	3258	486	87	NA		HR (95% CI): 1.34 (1.26 to 1.42)	1.08 (1.07 to 1.10)	0.93 (0.91 to 0.94)	0.81 (0.77 to 0.85)	0.78 (0.69 to 0.87)	0.75 (0.63 to 0.91)	0.73 (0.56 to 0.95)	NA		ARD (95% CI)†: 8 (6 to 10)	2 (2 to 2)	-2 (-2 to -1)	-5 (-6 to -4)	-5 (-8 to -3)	-6 (-9 to -2)	-7 (-11 to -1)	NA	MODERATE ^a
MET min/week	0	500	1000	2000	3000	4000	5000	6000																																																																								
Running (5 mph)*	0 hours/week	1 hour/week	2 hours/week	4 hours/week	6 hours/week	8 hours/week	10 hours/week	12 hours/week																																																																								
CVD mortality	Studies: 15	18	18	17	8	2	2	NA																																																																								
	Participants†: 579 901	986 340	279 319	286 717	111 007	19 489	5488	NA																																																																								
	Py†: 7721 115	9 761 494	3 860 943	3 796 251	1 165 769	274 344	65 089	NA																																																																								
	Total cases†: 12 318	30 196	8618	8661	3258	486	87	NA																																																																								
	HR (95% CI): 1.34 (1.26 to 1.42)	1.08 (1.07 to 1.10)	0.93 (0.91 to 0.94)	0.81 (0.77 to 0.85)	0.78 (0.69 to 0.87)	0.75 (0.63 to 0.91)	0.73 (0.56 to 0.95)	NA																																																																								
	ARD (95% CI)†: 8 (6 to 10)	2 (2 to 2)	-2 (-2 to -1)	-5 (-6 to -4)	-5 (-8 to -3)	-6 (-9 to -2)	-7 (-11 to -1)	NA																																																																								

Systematic review evidence Review credibility	No. of studies/ Study design No. of participants	Quality Assessment					Description of evidence Summary of findings	Certainty
		Risk of bias	Inconsistency	Indirectness †	Imprecision	Other		
Dinu 2019 (19) Low	9 prospective cohort studies N=177,239	Serious risk of bias	No serious inconsistency	Serious indirectness	No serious imprecision	None	All studies evaluated the effects of mixed mode (cycling and/or walking) active commuting on health outcomes. Exposure levels of active commuting were variably reported as minutes spent walking or cycling for transportation per day, as dichotomized variables (yes or no), or as METs with the reference category as no active commuting in most studies. Follow-up ranged from 4 to 25 years. There was no significant association between active commuting and CVD mortality compared with those participating in no active commuting (RR = 0.94 [95% CI 0.85 to 1.05], 9 studies).	LOW ^b
O'Donovan 2017 ^c (51) Good quality ^d	9 cohort studies N=37,059	No serious risk of bias	No serious inconsistency	No serious indirectness	Serious imprecision	None	Compared with those who met PA guidelines ^e and whose HDL-C was normal, CVD mortality risk was not significantly elevated in those who did not meet PA guidelines and whose HDL-C was normal (adjusted HR = 1.11 [95% CI, 0.82 to 1.52]); CVD mortality risk was elevated among those who did not meet PA guidelines and whose HDL-C was low (adjusted HR = 1.63 [95% CI 1.16 to 2.27]) compared with those meeting recommendations and with normal HDL-C.	LOW ^f
Siahpush 2019 ^g (63) Good quality ^d	Pooled cohort analysis N=68,706	No serious risk of bias	No serious inconsistency	No serious indirectness	No serious imprecision	None	Smokers who reported meeting aerobic and strengthening PA guidelines ^h (adjusted HR = 0.54 [95% CI, 0.39 to 0.76]), those meeting only aerobic PA guidelines (adjusted HR = 0.85 [95% CI 0.72 to 0.99]), and those meeting only strengthening exercise guidelines (HR = 0.63 [95% CI 0.43 to 0.93]) had significantly lower risk of CVD mortality than those not meeting both recommendations.	MODERATE ⁱ
Stamatakis 2018 ⁱ (65) Good quality ^d	Pooled cohort analysis N=80,306	No serious risk of bias	No serious inconsistency	No serious indirectness	No serious imprecision	None	There was no association between participation in any strength exercises vs. no participation (adjusted HR = 0.88 [95% CI, 0.71 to 1.08]) or meeting vs. not meeting the strength exercise guideline ^k (adjusted HR = 0.92 [95% CI 0.72 to 1.12]) and CVD mortality, including analysis limited to own-bodyweight exercises and gym-based exercises.	MODERATE ⁱ

Abbreviations: ARD = absolute rate difference; CI = confidence interval; CVD = cardiovascular disease; HDL-C = high-density lipoprotein cholesterol; HR = hazards ratio; MET =metabolic equivalent of task; min = minutes; MVPA = moderate-to-vigorous intensity physical activity; NR = not reported; RR = risk ratio; SB = sedentary behaviour

† Serious indirectness indicates measurement of intermediate/indirect outcomes or heterogeneity in exposures and comparisons assessed; certainty of evidence was not always downgraded for indirectness if it was not judged to impact the certainty in the findings for the outcome evaluated in the review

^a Certainty of evidence upgraded given no serious risk of bias of included studies and evidence of dose-response relationship; however, serious inconsistency (high between study variance, $I^2 > 77\%$) present; possible small studies effects/publication bias not judged as sufficient to warrant additional downgrading

^b Certainty of evidence not upgraded given serious risk of bias (not appropriately adjusting for confounding) and indirectness in comparisons of exposures

^c Not a systematic review. Pooled analysis of 9 population-based cohorts

^d Quality rated based on the Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses (77)

^e 150 min/week of moderate-intensity leisure time PA, or at least 75 min/week of vigorous-intensity leisure-time PA, or any combination of moderate- and vigorous-intensity PA equivalent to at least 7.5 MET-h/week

^f Certainty of evidence not upgraded given imprecision in estimates of effects (wide confidence interval representing range in results)

^g Not a systematic review. Pooled analysis of 1998-2009 National Health Index Survey and linked National Death Index

^h 150 min/week of moderate-intensity leisure time PA, or at least 75 min/week of vigorous-intensity leisure-time PA, or an equivalent combination and performing strengthening exercises ≥ 2 times/week

¹ Certainty of evidence upgraded given no serious limitations in included evidence

² Not a systematic review. Pooled analysis of 11 cohorts of the Health Survey for England and the Scottish Health Survey and linked to the British National Health Service Central Registry for data on mortality

³ Performing strengthening exercises ≥ 2 times/week

⁴ Certainty of evidence upgraded given no serious limitations in included evidence and evidence of dose-response relationship